Conference Faculty

Course Directors
National Corporate Medical Associates Conference
WILLIAM SCHNEIdER MD, MPH STEpHEN VEACH, MD COLIN BAIGEL, MD

Founder, NCMA
Course Director Founder, NCMA Member Emeritus, Memorial Sloan Kettering Cancer Center

Attending Physician MSKCC Employee Health and Wellness Services Memorial Sloan-Kettering Cancer Center

Medical Director, NCMA Attending Physician Thoracic Oncology Division of Solid Tumor Oncology Department of Medicine Memorial Sloan-Kettering Cancer Center

Corporate Medical Director, Bristol-Myers Squibb Dr Colin Baigel is a graduate of the School of Medicine, University of Cape Town, South Africa

THOMAs FAHEY, MD

Dr. Schneider was born in New York City and graduated from the College of Physicians & Surgeons of Columbia University. After internship in Internal Medicine at the University of Chicago and a residency in Internal Medicine at The New York Hospital, he completed a fellowship in Infectious Diseases and Immunology at the NYU Medical Center. He holds board certifications in Internal Medicine and Infectious Diseases. His previous academic appointment was at the Albert Einstein College of Medicine where he held the rank of Associate Clinical Professor of Medicine and Epidemiology. He is currently an Assistant Professor of Clinical Medicine at the Weill Cornell Medical College and an Adjunct Assistant Professor of Preventive Medicine at the Mount Sinai School of Medicine. Prior to his previous position as Corporate Medical Director of JP Morgan and then JP Morgan Chase, which he held more than 20 years, Dr. Schneider was the Assistant Director of the Department of Medicine at Montefiore Medical Center in the Bronx. Prior to that, he had directed the Employee Health Service at Montefiore. He is a Fellow of the American College of Physicians and the American College of Occupational and Environmental Medicine of which he is a former member of the Board of Directors and speaker of the House of Delegates.

I am a senior medical oncologist who specializes in the diagnosis and treatment of lung cancer, gastrointestinal cancers, and cancers of unknown primary site. In addition, I have the expertise to see and evaluate patients who need to have an appropriate treatment plan for cancer. I am part of a multidisciplinary team of physicians who work in concert to provide the optimal care for a patient with cancer. As a member of the faculty at the Weill Cornell Medical College, I help to train medical students and residents.

Colin completed residency training in Family Medicine at Montefiore Hospital and Medical Center, Bronx, NY in 1980. He is board-certified in Family Medicine and in Preventive Medicine with sub-specialization in Occupational Medicine. Colin served as Regional Medical Director, US Postal Service 1980 to 1986; he moved to the IB M Corporation in Armonk, NY from 1986 to 1992, rising to Program Director, Corporate Health. Colin joined BristolMyers Squibb Company in 1992 as Senior Director Corporate Health. He was promoted to Corporate Medical Director in 1995 and to Vice President and Corporate Medical Director in 2010. Under Colins leadership the BMS Occupational Health programs received national recognition with the Corporate Health Achievement Award from the American College of Occupational and Environmental Medicine (ACOE M) in 2002.

Thomas Fahey Jr., MD was appointed Senior Vice President for Clinical Program Development of Memorial SloanKettering Cancer Center on February 12, 1996, after serving as Deputy Physician-in-Chief of Memorial Hospital for Cancer and Allied Diseases for 15 years. In this new position he assumed responsibility for developing and extending international relationships and programs. After 45 years of Clinical and Administrative appointments at MSKCC, Dr. Fahey was awarded Emeritus Status in February 2011. A graduate of Cornell University Medical College, Dr. Fahey completed his training in internal medicine at the Cornell Division at Bellevue Hospital and the Memorial Hospital for Cancer and Allied Diseases in New York in 1964. He was Chief Resident in Medicine at Memorial in 1965. He joined the staff at Memorial in 1966 and has served in a variety of leadership capacities, particularly in the area of outpatient services, which have become increasingly important in cancer care. As Associate Dean of Cornell University Medical College, he oversaw Memorial Sloan-Ketterings clinical graduate education programs for residents, fellows and medical students, as well as the CME program for doctors in practice. His clinical interests have been in the area of hormonal manipulation of endocrine related tumors.

NaTIonaL CoRpoRaTE MEDIcaL AssocIaTEs:

Standard of Care in Oncology

Memorial Sloan-Kettering Course Faculty

CAROL AGHAJANIAN, MD
Chief, Gynecologic Medical Oncology Service Attending Physician Division of Solid Tumor Oncology Department of Medicine

JOs BAsELGA, MD, PhD

Physician-in-Chief Memorial Sloan Kettering Cancer Center

GARY E. DENG, MD, PhD

Associate Attending Physician Integrative Medicine Service Department of Medicine

As a medical oncologist who focuses exclusively on the medical treatment of gynecologic cancers. Dr. Aghajanian leads Memorial Sloan-Kettering Cancer Centers research program in chemotherapy for patients newly diagnosed with ovarian cancer and have a particular expertise in the management of both advanced gestational trophoblastic disease (GTD) and germ cell tumors of the ovary. In addition, she is the co-principal investigator for Memorial Sloan-Kettering participation in the Gynecologic Oncology Group (GOG) and serve on the Phase I committee and the Medical Oncology Committee for the GOG. Her recent honors include a career development award from the American Society of Clinical Oncology and the Boyer Award for outstanding young investigators at Memorial SloanKettering Cancer Center.

I am a board-certified medical oncologist focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. In my clinical practice I care for women with all stages of breast cancer. I have devoted over 20 years of my career to the development of therapies against the Epidermal Growth Factor Receptor (EG FR) and the closely related HER 2 receptor. In the field of anti-HER 2 therapies, I was the lead investigator in the first publication that demonstrated clinical activity of the anti-HER 2 monoclonal antibody trastuzumab (Herceptin) in patients with advanced HER 2 over expressing breast cancer. I continue to lead state-of-the-art world-wide clinical trials with trastuzumab including in the neo-adjuvant and adjuvant setting. Before returning to Memorial Sloan-Kettering, I led the Vall dHebron Hospital in Barcelona, Spain. Thereafter I moved to the Massachusetts General Hospital in Boston to become Chief of the Hematology/Oncology Division and Associate Director of the Massachusetts General Cancer Center. As Physician-in-Chief at Memorial Sloan-Kettering, I oversee the clinical component of Memorial Sloan-Kettering Cancer Center. My responsibilities include the management of patient care delivery in Memorial Hospital as well as at Memorial Sloan-Ketterings clinics and regional sites. I am also focused on implementing the clinical strategic planning and in charge of enhancing Memorial Sloan-Ketterings clinical and translational research.

Many cancer patients are interested in complementary and alternative medicine. I help patients understand how some of these therapies can help while others can be counter-productive. I also counsel patients on what else they can do to help themselves before, during, and after cancer treatment, taking advantage of what integrative medicine has to offer. Integrative medicine can reduce symptoms, improve quality of life, facilitate disease prevention, and promote wellness. I am a principal investigator of several research projects on acupuncture and botanical/herbal agents, which are funded by the National Institutes of Health. I have authored review articles and medical textbook chapters on Integrative Medicine. These include Integrative Oncology Clinical Practice Guidelines adopted by the Society of Integrative Oncology and American College of Chest Physicians, and Integrative Medicine Research: Context and Priorities commissioned by the Institute of Medicine of the National Academy of Sciences. I have a particular interest in physician education. I am also active in the professional community and serve as the current president of the Society for Integrative Oncology.

Attending Radiologist Director, Thoracic Imaging Associate Director, Educational Programs Department of Radiology

MICHELLE S. GINsbERG, MD

Dr. Ginsberg is a radiologist who specializes in CT scanning of the body, with particular clinical and research expertise in lung cancer and lung metastases. Her major research interest involves radiologic detection and characterization of small lung nodules. She is also very interested in computer manipulation of CT images and am an active member of the Computer Imaging Laboratory in the Radiology Department, currently working on automatic detection and segmentation of tumors. She has participated in many multicenter trials assessing radiologic response in the treatment of advanced lung and renal cancers. She serves as Director of Cardiothoracic Imaging and am an integral part of the Thoracic Disease Management Team at MSKCC. As Associate Training Director of Educational Programs in Radiology, she is very involved in teaching residents and fellows in the Radiology Department.

www.mskcc.org/ncma

Conference Faculty

NCMA

Associate Attending Physician Myeloma Service Division of Hematologic Oncology Department of Medicine

HANI HAssOUN, MD

JOHN H. HEALEY, MD, FACS

Attending Surgeon Orthopedic Service Department of Surgery

Assistant Attending Physician Infectious Disease Service Division of General Medicine Department of Medicine

MINI KAMbOJ, MD

MAUREEN KILLACkEY MD, FACOG, FACS

Deputy Physician-in-Chief MSK Regional Care Network Attending Surgeon Gynecology Service Department of Surgery

I am a board-certified hematologist/ oncologist with a special interest in plasma cell dyscrasias a group of disorders that includes multiple myeloma, amyloidosis, light chain deposition disease, POE MS syndrome, and Waldenstrms macroglobulinemia. There have been tremendous advances in this field over the past decade, and several new drugs are available or in development to manage these conditions. With my colleagues at Memorial Sloan-Kettering Cancer Center, I have focused on developing and optimizing new approaches to treat these diseases, including both new drugs and new strategies to improve patients outcomes. In multiple myeloma we currently have several clinical trials that are addressing important questions in patients who are newly diagnosed and have never been treated to better define the role and timing of autologous stem cell transplantation. We are also conducting several clinical trials in patients whose disease has recurred after initial treatment. Likewise, in the field of amyloidosis and light chain deposition disease, we are currently testing the role of a comprehensive treatment that incorporates autologous stem cell transplantation preceded and followed by more conventional therapies. I also have a particular interest in thrombotic complications (blood clotting) that occur in cancer patients and in patients receiving chemotherapy.

With decades of experience diagnosing and treating sarcomas and benign tumors of the bones and soft tissue, I am an expert in surgery to remove tumors while preserving limbs, and I rebuild functional bones and joints with joint replacements and bone transplants. I am proud to be part of a team with a missionary zeal to treat people with cancer and to help them continue to have productive lives. I also have a special interest in treating children who have bone cancers (osteosarcoma and Ewing sarcoma). As we continue to make progress in curing these cancers, it becomes even more important to be able to reconstruct limbs to provide patients with optimal long-term function. My research involves understanding the molecular biology of sarcoma, developing new ways to deliver chemotherapy to tumors, and improving the durability and function of joint replacements. I have invented and developed four joint replacement systems and have patented several methods to deliver drugs to tumors and study cancers in the laboratory. In addition to Chief of the Orthopaedic Service at Memorial Sloan-Kettering, I am a Professor of Orthopaedic Surgery at Weill Cornell Medical College. Education is an important part of my role as well. I directed the Orthopaedics Fellowship Program at Memorial Sloan-Kettering for 20 years, and am proud to have trained leading specialists in North and South America, Europe, and Asia. Most importantly, I educate my patients about their disease and how we will respond effectively to meet their needs.

Dr. Kamboj is an Assistant Member in the Infectious Disease Service, Department of Medicine. She is also the Associate Hospital Epidemiologist at MSKCC. Her research focus is on performing translational studies implementing molecular diagnostics and fingerprinting techniques to elucidate transmission of hospital acquired pathogens (C. difficile, VRE and Respiratory viruses), and determine best infection control practices to curtail their spread.

As Deputy Physician-in-Chief and Medical Director of the Regional Care Network for Memorial Sloan-Kettering Cancer Center, I oversee and ensure the highest quality of multidisciplinary cancer care, expand clinical research protocols, and develop community and organizational collaborations at the Memorial Sloan-Kettering facilities in New York and New Jersey. I am also a board-certified gynecologic oncologist and have been caring for women with cancer since 1982. I am involved in a number of governmental and non-profit initiatives to improve the care of women with cancer. I chair the New York State Breast and Cervical Advisory Council, and am a member of the state Ovarian Cancer Advisory Panel and Cancer Center Directors Committee. And in my role as an At-Large member of the Eastern Division Board of Directors of the American Cancer Society for the States of New York and New Jersey I am involved in healthcare advocacy work and initiatives in both states.

NaTIonaL CoRpoRaTE MEDIcaL AssocIaTEs:

Standard of Care in Oncology

Assistant Attending Physician Leukemia Service Division of Hematologic Oncology Department of Medicine

VIRGINIA M. KLIMEk, MD

LEE M. KRUG, MD

Associate Attending Physician Thoracic Oncology Service Division of Solid Tumor Oncology Department of Medicine

Attending Physician Lymphoma Service Division of Hematologic Oncology Department of Medicine

CRAIG H. MOskOwITZ, MD

ROIsIN EILIsH OCEARbHAILL, MBBCH, BAO

I am a board-certified medical oncologist with a clinical and research focus on bone marrow failure syndromes, including myelodysplastic syndromes (MDS) and aplastic anemia. Because these conditions can sometimes turn into acute leukemia, I also have experience in the treatment of acute myelogenous leukemia (AML). My research interests also include the study of therapy-related MDS and leukemia, which can develop after treatment with radiation or chemotherapy for another cancer. I feel fortunate to be at Memorial Sloan-Kettering Cancer Center where we have a team approach to managing bone marrow failure syndromes. I work with pathologists who are dedicated to the study and review of bone marrow samples, and a stem cell transplant program that offers a full range of stem cell transplant options, including stem cell transplants for people with marrow diseases up to the age of 70. One of the strengths of our program is our ability to accurately diagnose bone marrow failure syndromes, which can mimic many other conditions. Because of their complexity, bone marrow failure syndromes require a carefully thought out, evolving care plan. One of my goals is to educate and empower my patients so they can participate fully in decision-making about their care.

My primary responsibility as a thoracic oncologist at Memorial Sloan-Kettering is to care for patients with lung cancer and malignant pleural mesothelioma. I also run clinical trials that test novel drugs and treatment strategies for individuals with small cell lung cancer and mesothelioma. I have a particular interest in therapies that boost the immune system to allow it to recognize and attack specific molecules on cancer cells. I have conducted studies testing cancer vaccines developed by scientists at our center in patients with small cell lung cancer and mesothelioma. As director of Memorial Sloan-Ketterings Mesothelioma Program, I head a multidisciplinary team of physicians and scientists dedicated to developing better treatment for the disease. Our group has led studies exploring the benefit of chemotherapy, surgery, and radiation for patients with early-stage mesothelioma. I have also led an international phase III trial of vorinostat for patients with mesothelioma who had previously been treated with chemotherapy. I also direct the committee that establishes the National Comprehensive Cancer Networkguidelines for the management of mesothelioma, and I serve as Chair of the Science Advisory Board for the Mesothelioma Applied Research Foundation. In addition, I am co-director of Memorial SloanKetterings Medical Oncology/ Hematology Fellowship Training Program.

I specialize in the care of patients with Hodgkin and non-Hodgkin lymphoma. I am Clinical Director of the Division of Hematologic Oncology and I am boardcertified in internal medicine, medical oncology, and hematology. Recognizing that advances in medicine come about as a result of clinical research, I am the Principal Investigator for a number of clinical trials aimed at improving the care of patients with lymphoma. The findings of several of the clinical trials I have led have changed the international standard of care. My research has focused on improving the outcome of patients with poor-risk diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). This effort has been conducted along two tracks. One effort is focused on improving therapy for patients with disease that has returned or is not responding to standard therapy (refractory disease), through the use of high-dose therapy and autologous stem cell transplantation as well as new agents that can be incorporated into such salvage therapy. A second approach involves developing strategies to optimize the treatment of newly diagnosed DLBCL according to the likelihood of their disease recurring (risk-adapted therapy), using what we have learned by studying patients with relapsed or refractory disease. We design risk-adapted therapy according to a patients risk factors before treatment (clinical, molecular, or pathologic features of the disease) and the results of imaging studies.

Assistant Attending Physician Gynecologic Medical Oncology Service Division of Solid Tumor Oncology Department of Medicine

Attending Physician Lymphoma Service Division of Hematologic Oncology Department of Medicine

KENNETH OffIT, MD

I am a medical oncologist with a primary focus on the medical treatment of patients with gynecologic cancers. I work very closely with a team of surgeons, oncologists, and radiation therapists to determine and provide the best treatment for each patient with these diseases. My research initiatives include improving the treatment options for women with recurrent ovarian cancer.

I am a medical oncologist with clinical and laboratory experience in cancer genetics. My research focuses on defining genetic factors that cause an increased susceptibility to cancer. My research team identified the most common mutation associated with an increased risk of breast and ovarian cancer among individuals of Ashkenazi Jewish ancestry. My MSKCC colleagues and I also published the first prospective series describing the outcome of preventive ovarian surgery and screening in women at hereditary risk for breast and ovarian cancer. Ongoing research is aimed at defining new genetic risk factors and tailored interventions for families at hereditary risk for cancers of the breast, ovary, colon, prostate, and lymphoid organs. I have served as a member of the National Cancer Institutes Cancer Genetics Working Group, chaired the subcommittee on cancer genetics of the American Society of Clinical Oncology, and serve on a number of local and federal advisory committees dealing with cancer genetic testing and genomic risk profiling.

www.mskcc.org/ncma

Conference Faculty

NaTIonaL CoRpoRaTE MEDIcaL AssocIaTEs:

Standard of Care in Oncology

NCMA

HOwARd I. SCHER, MD

Chief, Genitourinary Oncology Service Attending Physician Division of Solid Tumor Oncology Department of Medicine

MONIkA SHAH, MD

Associate Attending Physician Infectious Disease Service Division of General Medicine Department of Medicine

Attending Physician Breast Cancer Medicine Service Division of Solid Tumor Oncology Department of Medicine

ANdREw D. SEIdMAN, MD

CONsTANTINOs T. SOfOCLEOUs, MD, PhD

Associate Member Department of Radiology

I am Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering and a board certified medical oncologist with special expertise in treating men with advanced prostate cancer. Under my leadership, the Genitourinary Oncology Service program is dedicated to the treatment of prostate cancer, testicular cancer, bladder and upper-tract urothelial cancer, and kidney cancer. Our objective is to foster synergy between scientific research and clinical practice, and to ensure that promising scientific discoveries are used to develop new diagnostic tests and treatments for patients. My own research is focused on three critical areas: developing treatments that target specific signaling pathways that contribute to prostate cancer growth, developing non-invasive methods to determine whether these agents are working, and improving the way drugs are evaluated in the clinic. In addition to serving as Chief of the Genitourinary Oncology Service for the past 16 years, I am the incumbent of the D. Wayne Calloway Chair in Urologic Oncology and a Professor of Medicine at the Weill Cornell Medical College.

I am a physician specializing in diagnosing and managing a broad range of infectious diseases. I have a particular interest in HIV infection. I also have an interest in International Health and participate in a Travel Clinic that is available to patients who are in need of pre-travel counseling and vaccinations. I am also responsible for Graduate Medical Education in the Department of Medicine. I oversee the Department of Medicines Internal Medicine Rotation, and in that role I am committed to the education and training of our medical residents so that they are enabled to deliver excellent and compassionate medical care during their time at Memorial Sloan-Kettering.

I am a medical oncologist with expertise in the management of both early stage and advanced breast cancer. My research interests include the clinical investigation of novel chemotherapeutic and targeted agents in the treatment of metastatic breast cancer.

I have been practicing interventional radiology since 1998, and joined the division of interventional radiology and image guided therapies at Memorial Sloan-Kettering Cancer Center in 2002. As an expert in interventional oncology, I use minimally invasive procedures performed with image guidance to diagnose and treat cancer patients with minimal side effects, complications, and discomfort.

www.mskcc.org/ncma